Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|August 31, 2025
[An integrative drug discovery strategy using real-world data, in silico modeling, and network pharmacology]Hirofumi Hamano, Yuta Tanaka, Yoshito Zamami
Acta Medica Okayama|February 27, 2025
Photoinitiators Induce Histamine Production in Human Mast CellsTaro Miura, Yoichi Kawasaki, Hirofumi Hamano, et al.
Clinical and Translational Science|August 18, 2025
Cardiotoxicity Assessment of EGFR Tyrosine Kinase Inhibitors Using Human iPS Cell-Derived Cardiomyocytes and FDA Adverse Events Reporting SystemShota Yanagida, Hiroyuki Kawagishi, Mitsuo Saito, et al.
European Journal of Clinical Pharmacology|October 23, 2024
Evaluating the impact of loperamide on irinotecan-induced adverse events: a disproportionality analysis of data from the World Health Organization pharmacovigilance database (VigiBase)Tomoaki Akagi, Hirofumi Hamano, Hirotaka Miyamoto, et al.
Frontiers in Pharmacology|June 28, 2021
Evaluation of Potential Complications of Interstitial Lung Disease Associated With Antiandrogens Using Data From Databases Reporting Spontaneous Adverse EffectsHideki Nawa, Takahiro Niimura, Hirofumi Hamano, et al.
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|March 3, 2024
[Development of Preventive Methods for Drug-induced Cardiotoxicity Using a Large-scale Medical Information Database]Hirofumi Hamano, Yoshito Zamami, Soichiro Ushio, et al.
British Journal of Clinical Pharmacology|November 22, 2023
Influence of vasopressin receptor antagonists on triple-whammy acute kidney injury: A VigiBase analysisSatoru Mitsuboshi, Kenji Hayakawa, Hirofumi Hamano, et al.
JACC. Cardiooncology|September 12, 2025
Risk of Heart Failure Hospitalization in Patients Treated With Osimertinib: A Population-Based Retrospective Cohort StudyYasuhisa Tatebe, Yuta Tanaka, Yohei Manabe, et al.
British Journal of Clinical Pharmacology|May 9, 2025
Comprehensive analysis of adverse event profile changes with pertuzumab addition to trastuzumab-based breast cancer therapy: Disproportionality analysis using VigiBaseTatsuaki Takeda, Jun Matsumoto, Tomonori Sakai, et al.
Clinical and Translational Science|September 21, 2022
Evaluation of the potential complication of interstitial lung disease associated with antifibrotic drugs using data from databases reporting spontaneous adverse effectsHideki Nawa, Hirofumi Hamano, Takahiro Niimura, et al.
Pageof 9